Novavax reports Phase II maternal RSV vaccine results

Novavax Inc. (NASDAQ:NVAX) fell $1.74 (21%) to $6.41 after it announced top-line results from a Phase II study of its RSV F vaccine for respiratory syncytial virus (RSV) to protect infants via maternal immunization. Although it reported that the vaccine was safe and well tolerated, analysts expressed concern over antibody responses in the maternal population.

Novavax also said the Bill and Melinda Gates Foundation granted the company up to $89 million to support a Phase III trial of the vaccine in pregnant women, scheduled to start in 1Q16. ...